BioNexus Gene Lab Corp. (BGLC)
NASDAQ: BGLC · Real-Time Price · USD
0.263
+0.003 (0.96%)
Dec 19, 2024, 4:00 PM EST - Market closed
BioNexus Gene Lab Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2016 |
| Revenue | 9.26 | 9.77 | 10.93 | 13.36 | 11.39 | 0.13 | Upgrade
|
| Revenue Growth (YoY) | -10.42% | -10.60% | -18.21% | 17.31% | 8872.03% | -40.21% | Upgrade
|
| Cost of Revenue | 8.01 | 8.44 | 9.67 | 11.1 | 9.67 | 0.07 | Upgrade
|
| Gross Profit | 1.25 | 1.33 | 1.26 | 2.27 | 1.72 | 0.06 | Upgrade
|
| Selling, General & Admin | 1.34 | 2.23 | 1.73 | 1.28 | 1.33 | 0.36 | Upgrade
|
| Other Operating Expenses | -0.99 | -0.17 | -0.25 | -0.07 | -0.18 | -0.03 | Upgrade
|
| Operating Expenses | 1.66 | 3.37 | 1.48 | 1.21 | 1.15 | 0.33 | Upgrade
|
| Operating Income | -0.41 | -2.04 | -0.22 | 1.06 | 0.57 | -0.28 | Upgrade
|
| Interest Expense | -0.02 | -0.01 | -0.01 | -0.01 | -0.01 | - | Upgrade
|
| Other Non Operating Income (Expenses) | -0.87 | -0.87 | - | - | - | - | Upgrade
|
| EBT Excluding Unusual Items | -1.3 | -2.92 | -0.23 | 1.04 | 0.56 | -0.28 | Upgrade
|
| Gain (Loss) on Sale of Investments | 0.38 | 0.31 | -0.07 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | 0.71 | - | Upgrade
|
| Pretax Income | -0.92 | -2.61 | -0.3 | 1.04 | 1.26 | -0.28 | Upgrade
|
| Income Tax Expense | 0.02 | 0.02 | 0.05 | 0.29 | 0.17 | -0.03 | Upgrade
|
| Net Income | -0.94 | -2.63 | -0.36 | 0.75 | 1.09 | -0.25 | Upgrade
|
| Net Income to Common | -0.94 | -2.63 | -0.36 | 0.75 | 1.09 | -0.25 | Upgrade
|
| Net Income Growth | - | - | - | -31.31% | - | - | Upgrade
|
| Shares Outstanding (Basic) | 18 | 16 | 14 | 14 | 9 | 7 | Upgrade
|
| Shares Outstanding (Diluted) | 18 | 16 | 14 | 14 | 9 | 7 | Upgrade
|
| Shares Change (YoY) | 18.10% | 10.17% | 0.99% | 66.36% | 19.16% | 30.20% | Upgrade
|
| EPS (Basic) | -0.05 | -0.17 | -0.02 | 0.05 | 0.13 | -0.03 | Upgrade
|
| EPS (Diluted) | -0.05 | -0.17 | -0.02 | 0.05 | 0.13 | -0.03 | Upgrade
|
| EPS Growth | - | - | - | -58.71% | - | - | Upgrade
|
| Free Cash Flow | -2.65 | -1.45 | 0.5 | 0.01 | 0.13 | -0.23 | Upgrade
|
| Free Cash Flow Per Share | -0.15 | -0.09 | 0.03 | 0.00 | 0.02 | -0.03 | Upgrade
|
| Gross Margin | 13.46% | 13.61% | 11.52% | 16.96% | 15.10% | 44.02% | Upgrade
|
| Operating Margin | -4.45% | -20.90% | -2.02% | 7.90% | 4.98% | -217.17% | Upgrade
|
| Profit Margin | -10.17% | -26.91% | -3.26% | 5.62% | 9.61% | -194.14% | Upgrade
|
| Free Cash Flow Margin | -28.62% | -14.85% | 4.55% | 0.04% | 1.15% | -181.24% | Upgrade
|
| EBITDA | -0.32 | -1.96 | -0.13 | 1.15 | 0.66 | -0.23 | Upgrade
|
| EBITDA Margin | -3.43% | -20.05% | -1.18% | 8.58% | 5.77% | -184.31% | Upgrade
|
| D&A For EBITDA | 0.09 | 0.08 | 0.09 | 0.09 | 0.09 | 0.04 | Upgrade
|
| EBIT | -0.41 | -2.04 | -0.22 | 1.06 | 0.57 | -0.28 | Upgrade
|
| EBIT Margin | -4.45% | -20.90% | -2.02% | 7.90% | 4.98% | -217.17% | Upgrade
|
| Effective Tax Rate | - | - | - | 27.93% | 13.34% | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.